SR13668 / SRI International - LARVOL DELTA

3,3'-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways. (PubMed, Cancer Cell Int) - "Via this study, we update the existing knowledge of the state of anti-cancer investigation concerning I3C and DIM chemicals. We have also summarized; (i) the recent advancements in the use of I3C/DIM as therapeutic molecules since they represent potentially appealing anti-cancer agents, (ii) the available literature on the I3C and DIM characterization, and the challenges related to pharmacologic properties such as low solubility, and poor bioavailability, (iii) the synthesis and semi-synthetic derivatives, (iv) the mechanism of anti-tumor action in vitro/in vivo, (v) the action in cellular signaling pathways related to the regulation of apoptosis and anoikis as well as the cell cycle progression and cell proliferation such as peroxisome proliferator-activated receptor and PPARγ agonists; SR13668, Akt inhibitor, cyclins regulation, ER-dependent-independent pathways, and their current medical applications, to recognize research opportunities to potentially use these..."

Journal • Review • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Gynecology • Oncology • Prostate Cancer • Solid Tumor

Enhanced oral bioavailability of a cancer preventive agent (SR13668) by employing polymeric nanoparticles with high drug loading (J Pharm Sci.) - Nanoparticle encapsualted SR13668 was developed; The optimized formulation achieved high drug loading (33.3 wt %) and small particles (150 nm) with narrow size distribution was prepared; In vitro release of SR13668 from the nanosuspensions was measured in a solution with separated organic and aqueous phases to overcome the limit of SR13668 low water solubility; Higher oral bioavailability of SR13668 by employing polymeric nanoparticles compared with the Labrasol formulation was demonstrated in a mouse model

Preclinical-animal • Oncology